![]() ![]() How their therapeutic prevents tau from misfolding and forming tangles that harm neurons, and.Why Oligomerix chose to focus on the tau protein when many other companies were working with amyloid,.On a hopeful note, James Moe emphasizes how close the neurodegeneration research community is to developing significant breakthroughs. This podcast discusses research on a particular drug that’s showing promise, but also helps with understanding Alzheimer’s disease progression. There are still no disease-modifying therapeutics for dementia patients, but James Moe thinks that will change soon. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |